MedTrace Logo

Comparative Effectiveness of Targeted Therapy in RA Patients

NCT04449224 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 506

Last updated 2020-06-26

No results posted yet for this study

Summary

The objective of a multicenter prospective observational study is to compare effectiveness and safety of biologic disease-modifying antirheumatic drugs and small molecular inhibitors in patients with moderately to severely active rheumatoid arthritis patients who have had an inadequate response or intolerace to methotrexate.

Conditions

Interventions

DRUG

Adalimuab, Etanercept, Tocilizumab, or Abatacept

A specific targeted therapy wil be decided by shared-decision making, a bidirectional process in which clinicians and patients make decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.

DRUG

Tofacitinib or Baricitinib

A specific targeted therapy wil be decided by shared-decision making, a bidirectional process in which clinicians and patients make decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.

Sponsors & Collaborators

  • Ministry of Health, Republic of Korea

    collaborator OTHER_GOV

  • Hanyang University

    lead OTHER

Principal Investigators

  • Yoon-Kyoung Sung, MD, PhD, MPH · Hanyang University

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-27
Primary Completion
2023-08-19
Completion
2024-08-19

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04449224 on ClinicalTrials.gov